Navigation Links
Letter from Alliqua CEO, Dave Johnston, to Shareholders

for sustained growth in the future.

Capital Conservation and Growth

We recently completed a round of financing by our insiders which I believe demonstrates the confidence we have in our ability to build Alliqua for the future.  These funds are expected to be allocated toward the revenue-generating efforts I described earlier. While funding is vital to any company, success is driven by more than just capital. I believe the changes we made in 2012, including the strategic differentiation of our Alliqua Biomedical and AquaMed Technologies divisions, provides Alliqua with the foundation necessary to achieve our vision to become a world-class wound-care and topical drug delivery business. 

In conclusion, I would like to thank our stockholders, advisors and colleagues who believe in this company and remain committed to its success. I look forward to continuing our work together in 2013 as we strive to execute on our plans, increase revenue and create outstanding returns for our company and its stockholders for years to come.  I wish you all well and look forward to updating you on our accomplishments throughout the year.

Warm Regards,

Dave Johnson
Alliqua, Inc.

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510K FDA-approved hydrogel products for wound care under the SilverSeal® brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne PA, allows Alliqua to aggressively develop

SOURCE Alliqua, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. HealthEconomics.Com Announces Newsletter Promoting Health Outcomes and Pharma Reimbursement Jobs
2. HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter
3. Topical BioMedics' Newsletter Dedicated to Natural Healing and Wellness--New Issue Available Online
4. First Warning Systems and Unicorp Biotech International Strategic Partner Letter of Intent Signed Breast Cancer Early Detection
5. Amarantus BioSciences Issues CEO Letter to Shareholders
6. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
7. Ronald L. Chez Files Amended 13D and Letter to the Board
8. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
9. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
10. Genesis Biopharma Issues Letter To Shareholders
11. NeoStems CEO Letter to Shareholders
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Sept. 7 On Thursday, October,18, 2007, Wyeth (NYSE: ... 2007,third quarter. The Company will hold a one-hour conference ... October 18, 2006. Interested,investors and others may listen to ... Internet webcast, which may be accessed by visiting our ...
... Richard Gabriel, Chief,Executive Officer of DNAPrint Genomics, ... be featured in an exclusive interview with, ... September 10 at 11,a.m. EDT. The interview will ... p.m.,EDT on September 10. The interview will ...
... York City 5:30-7:30 p.m. (ET), SAN DIEGO, Sept. ... focused on developing products for,minimally disruptive surgical treatments for ... reception for institutional investors and,analysts at the Waldorf=Astoria Hotel ... 5:30 p.m. to 7:30 p.m. ET. The reception ...
Cached Biology ( Announces Upcoming Interview With CEO of DNAPrint Genomics 2NuVasive to Host Investor Reception on September 11, 2007 2NuVasive to Host Investor Reception on September 11, 2007 3NuVasive to Host Investor Reception on September 11, 2007 4
(Date:10/22/2014)... discovery by Northwestern Medicine® scientists helps explain how bipolar ... to new drug therapies to treat the mental illness. ... -- the same method recognized with the 2014 ... into brain tissue from mice with bipolar-like behaviors. In ... discovered tiny "nanodomain" structures with concentrated levels of ANK3 ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... biochemists have developed an approach that allows them to ... in a protein. The scientists were then able ... protein based on structural information, a novel outcome that ... Academy of Sciences. , Professor of biochemistry John Markley, ...
... are so crucial to survival that the brains of all ... long enough to allow the animal to eat, drink -- ... from researchers at the University of Chicago, published early online ... that by activating "OFF" cells and shutting down "ON" cells ...
... classic "Flowers for Algernon," but adds a happy ending, UCLA ... reverse the attention deficits linked to the leading genetic cause ... Biology reports the findings, which were studied in mice bred ... , The results proved so hopeful, that the Food and ...
Cached Biology News:Scientist uses form to explain function of key building blocks of life 2Brainstem blocks pain to protect key behaviors 2Brainstem blocks pain to protect key behaviors 3Recreating 'Flowers for Algernon' with a happy ending 2Recreating 'Flowers for Algernon' with a happy ending 3
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: